New email from Theralase I hope you're having a great week.
Theralase has been bustling with exciting developments over the past week, and we want to share some of the remarkable news with you:
- Theralase® Technologies Inc. announced that our lead compound, Ruvidar™, has shown effectiveness in inactivating several viruses, including H1N1 influenza virus, coronavirus, Zika virus, poxvirus, and herpes virus. Notably, at a concentration of 3 mM, Ruvidar™ completely eradicated the herpes virus. Theralase(R) Technology Effective in Virus Inactivation (accesswire.com)
- We are thrilled to report that Ruvidar™, when combined with transferrin to form Rutherrin®, has demonstrated preclinical effectiveness in destroying Non-Small Cell Lung Cancer (NSCLC). Theralase(R) Successfully Destroys Lung Cancer (accesswire.com)
- Our preclinical research shows that Ruvidar™, in combination with Bacillus Calmette-Gurin (BCG), significantly enhances the cancer cell-killing efficacy compared to BCG or Ruvidar™ alone, even without light activation. Ruvidar(TM) Enhances Efficacy of Cancer Drug (accesswire.com)
- We are also pleased to announce that Rutherrin® has been proven in preclinical studies to enhance the efficacy of chemotherapy and reduce multidrug resistance. Rutherrin(R) Increases Efficacy of Chemotherapy (accesswire.com)
Additionally Theralase® will be hosting a virtual presentation on Wednesday June 19th , 2024 at 5:30 pm ET immediately following the Annual General and Special Meeting or AGSM which will include a live Corporate Presentation and provide an opportunity for virtual guest to submit their questions to a live question and answer period to follow.
Zoom Meeting Link: https://us02web.zoom.us/j/83200739937
Conference Call in: 1-647-558-0588 (Canada) / 1-646-558-8656 (US) - not required for those attending by Zoom.
An archived version will be available on the website following the conference call.
If you would like to discuss any of these updates or explore investment opportunities with Theralase®, please don't hesitate to reach out to me directly.
Thank you,
Matthew
Interested in discussing our stock? click here to book an appointment